Home > Insider Trading > Filing (0001661181-21-000013)

Filing Details

Accession Number:: 0001661181-21-000013
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-16 21:57:50
Reporting Period:: 2021-02-11

Accepted Time:: 2021-02-16 21:57:50
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1661181	Organogenesis Holdings Inc.	ORGO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1757373	S. Gary Gillheeney	C/O Organogenesis Holdings Inc. 85 Dan Road Canton MA 02021	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class A Common Stock	Disposition	2021-02-11	69,127	$13.82	416,954	No	4	S	Direct
Class A Common Stock	Disposition	2021-02-12	77,938	$12.96	339,016	No	4	S	Direct
Class A Common Stock	Disposition	2021-02-12	33,391	$13.77	305,625	No	4	S	Direct
Class A Common Stock	Disposition	2021-02-16	111,406	$13.12	194,219	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2020.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $14.22, inclusive. The reporting person undertakes to provide to Organogenesis Holdings Inc. ("ORGO"), any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.565 to $13.53, inclusive. The reporting person undertakes to provide to ORGO, any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.58 to $14.02, inclusive. The reporting person undertakes to provide to ORGO, any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.71 to $13.67, inclusive. The reporting person undertakes to provide to ORGO, any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.